RECONCILIATION OF GAAP RESEARCH AND DEVELOPMENT EXPENSES TO NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES
| Three Months Ended March 31, | Twelve Months Ended March 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Research and development expenses, as reported | $ | 240.3 | $ | 298.3 | $ | 1,097.4 | $ | 1,118.3 | |||||||
| Share-based compensation expense | (23.3 | ) | (22.0 | ) | (94.3 | ) | (83.1 | ) | |||||||
| Other adjustments | — | (0.2 | ) | (0.5 | ) | (0.8 | ) | ||||||||
| Non-GAAP research and development expenses | $ | 217.0 | $ | 276.1 | $ | 1,002.6 | $ | 1,034.4 | |||||||
| GAAP research and development expenses as a percentage of net sales | 18.1 | % | 13.4 | % | 14.4 | % | 13.3 | % | |||||||
| Non-GAAP research and development expenses as a percentage of net sales | 16.4 | % | 12.4 | % | 13.1 | % | 12.3 | % | |||||||
